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Background: Inhalation studies suggested “protective” roles of exogenous prostaglandin E2, but the
clinical relevance of endogenous prostanoids in asthma is poorly known. The objective of this study is to
measure sputum levels of prostanoids in asthmatic patients to correlate with clinical indices.
Methods: Mild (n ¼ 41) or moderate-to-severe (19) asthmatics and 27 normal controls were examined
for pulmonary function (FEV1 and mid-forced expiratory ﬂow), sputum cell differentials, and sputum
levels of prostaglandins D2, E2, F2a, and thromboxane B2 measured by sandwich enzyme immunoassay.
Results: Each prostanoid level did not differ among the three groups. Sputum number of bronchial
epithelial cells was greater in moderate-to-severe asthmatics than in the other two groups, suggesting
epithelial desquamation. Levels of prostaglandin F2a, D2, and thromboxane B2 positively correlated with
the severity of airﬂow obstruction in the 60 asthmatic patients, whereas prostaglandin E2 levels were
unrelated to pulmonary function. The ratio of combined “contractile” prostanoids (prostaglandin D2/
prostaglandin F2a/thromboxane B2) to prostaglandin E2 was 2.5-fold greater in moderate-to-severe
asthmatics than in controls (p ¼ 0.001) or in mild asthmatics (p ¼ 0.0002) but did not differ between
the latter two groups. In the two asthmatic groups combined, this ratio positively correlated with the
sputum number of epithelial cells. The combined “contractile” prostanoids levels positively correlated
with prostaglandin E2 levels in controls and in mild asthmatics but not in moderate-to-severe
asthmatics.
Conclusions: An imbalance in production, breakdown, or both between prostaglandin E2 and other
prostanoids possibly due to epithelial damage may be involved in the pathogenesis of moderate-to-
severe asthma.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Asthma is a chronic inﬂammatory disease of the airways, which
involves inﬂammatory mediators such as histamine, cysteinyl leu-
kotrienes, platelet-activating factor and prostanoids.1 Prosta-
glandin (PG) D2, PGF2a, and thromboxane (TX) A2 have contractile
effects on airway smooth muscle in vitro,2,3 and cause broncho-
constriction in asthmatic subjects when inhaled.4,5 These prosta-
noids may thus exert deleterious effects in the pathophysiology ofMedicine, Allergy and Clin-
edical Sciences, Mizuho-ku,
iimi).
ety of Allergology.
rgology. Production and hosting by Elseasthma. In contrast, inhaled PGE2 attenuates allergen-induced early
and late asthmatic responses, airway hyperresponsiveness, and
inﬂammation characterized by the increased number of eosino-
phils.6 Inhaled PGE2 also protects against aspirin-induced exacer-
bation of asthma through mechanisms unrelated to its
bronchodilatory activity.7 PGE2, when exogenously administered,
may thus exert bronchoprotective and anti-inﬂammatory effects.
Despite PGE2 is contractile via EP1 and EP3 receptor in mice and
human whereas relaxant via EP2 receptor in mice and human and
EP4 in human,8,9 the net effect of PGE2 is therefore considered
“inhibitory”. Though a variety of cells have the capacity to release
prostanoids in the asthmatic airways,10 PGD2, and its metabolite,
9a,11b-PGF2 are primarily mast cell products,11 while PGE2 is pri-
marily a product of epithelial cells.1 Desquamation or damage of
epithelial cells may be characteristic of more severe asthma.12e14vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
M. Takemura et al. / Allergology International 66 (2017) 83e8884The levels of endogenous prostanoids in the airway surface
liquid of asthmatic patients and healthy controls have been
examined in samples of bronchoalveolar lavage, sputum, and
exhaled breath condensate.15e21 Previous studies have suggested
that airway levels of some prostanoids are increased in subsets of
asthmatic patients, such as smokers,19 but failed to show a relation
to asthma severity or activity.
We measured sputum levels of PGD2, PGE2, PGF2a, and TXB2 in a
large number of nonsmoking, asthmatic patients and healthy
controls. These levels were compared among patients with mild
asthma, those with moderate-to-severe asthma, and controls, and
were examined with respect to pulmonary function in the patients.
We then compared the ratio of combined “contractile” prostanoids
(PGD2, PGF2a, and TXB2), each of which was associated with airﬂow
obstruction in the patients, to PGE2 levels among the three groups,
on the hypothesis that the ratio of constrictor to dilator prostanoids
are increased in asthma dependent on asthma severity.
Methods
Study design
This was a cross-sectional study. To investigate the role of
endogenous prostanoids in asthma, we measured sputum levels of
PGD2, PGE2, PGF2a, and TXB2 in steroid-naïve asthmatic patients to
correlate with clinical indices.
Subjects
Sixty asthmatic and 27 healthy subjects including members of
our hospital staff, from whom adequate sputum samples were
obtained, were studied between March 2002 and June 2005.
Asthma was diagnosed according to the Global Initiative for
Asthma.22 The inclusion criteria of asthmatic patients were as fol-
lows: symptomatic but without exacerbations during the previous
one month, no history of aspirin-sensitive asthma or nasal polyps,
and taking only short-acting inhaled beta-2 agonists as needed.
They were steroid-naïve asthmatics or those who had been given
inhaled corticosteroid but voluntary discontinued it for more than
one month before presentation to our clinic. For patients who ful-
ﬁlled the entry criteria, sputum induction was performed followed
by asthma therapy including inhaled corticosteroid. After the
minimal medication required to maintain control had been deter-
mined, the severity of asthma was subsequently evaluated and
classiﬁed as mild for 41 patients (steps 1 and 2) and moderate-to-
severe for 19 patients (steps 3 and 4).22
During the month before the study, no subject, including con-
trol, had a respiratory tract infection, or had taken any anti-
leukotriene drugs, thromboxane synthase inhibitors or receptor
antagonists, cyclooxygenase inhibitors, or angiotensin-converting-
enzyme inhibitors. All participants were lifetime nonsmokers,
and had no evidence of COPD.
The study was approved by our Institutional Review Board (the
ethics approval number: E-715), and written informed consent was
obtained from all subjects.
Induced sputum production and processing
Sputum induction and processing were performed as
described.23e25 Brieﬂy, the subjects premedicated with 200 mcg of
salbutamol inhaled hypertonic (3%) saline solution for 15 min,
delivered by an ultrasonic nebulizer (MU-32, Azwell, Osaka, Japan).
Patients were then asked to try to cough sputum into a plastic petri
dish. No signiﬁcant bronchoconstriction was observed during the
procedure.All adequate plugs of sputum were separated from saliva and
were weighed. The plugs were treated with 0.1% dithiothreitol
(DTT) (Sputasol™, OXOID, Hampshire, UK), 2 times the weight of
the sputum sample. The samples were then treated with the same
volume of Dulbecco's phosphate buffered saline. After centrifuga-
tion at 1000 g for 10 min, the supernatants were stored at 80 C.
The cell pellet was resuspended in PBS solution. The total cell
count, excluding squamous cells, was determined with a standard
hemocytometer and expressed as cells 105/g wet weight sputum.
Then the cells were centrifuged and stained by the May-Grünwald-
Giemsa method. Cell differentials were determined by counting at
least 400 non-squamous cells.
Measurement of sputum levels of inﬂammatory mediators
As we previously described,25 concentrations of PGD2, PGE2,
PGF2a, and TXB2 in the sputum supernatant were measured with
the use of commercially available sandwich enzyme immunoassay
kits (PGE2: Amersham Biosciences, NJ, USA; PGD2-methoxime,
PGF2a, TXB2: Cayman Chemical, Ann Arbor, MI, USA), according to
the manufacturers' instructions. Duplicate measurements were
averaged for analysis. Coefﬁcient of variation for the duplicate
measurements was 3.9 (2.1e5.8) % for PGE2. Because PGD2 and
TXA2 are both relatively unstable compounds, we measured PGD2-
methoxime (PGD2-MOX) and TXB2, stable derivatives of PGD2 and
TXA2,18,25,26 respectively. The detection limit was 40 pg/ml for PGE2,
8 pg/ml for PGF2a, 3.1 pg/ml for PGD2-MOX, and 13 pg/ml for TXB2.
The results were presented as per gram of sputum.
Pulmonary function
Pre-bronchodilator values of FEV1, and mid-forced expiratory
ﬂow (FEF25e75%), were measured using a spirometer (Chestac-
65V™, Chest, Tokyo, Japan) before sputum induction.27
Statistical analysis
Data are expressed as medians (25the75th percentiles), and
analyzed with the StatView 5.0 program (SAS Institute, Cary, NC,
USA). The ManneWhitney U-test or Fisher's exact probability test
was performed to compare two groups. Comparison of three
groups was made by the KruskaleWallis test followed by Man-
neWhitney U-test, ANOVA followed by Fisher's PLSD test, or chi-
square test as appropriate. Spearman's rank correlation test was
used to analyze correlations. P values < 0.05 were considered sta-
tistically signiﬁcant.
Results
Characteristics and outcome of asthmatic patients and control
subjects
The characteristics of the control subjects and the two asthmatic
groups are shown in Table 1. Age differed among the three groups,
and the controls were signiﬁcantly younger than both asthmatic
groups. The distribution of sex, duration of asthma, total IgE levels,
and prevalence of atopy did not differ between patients with mild
asthma and those with moderate-to-severe asthma. FEV1 and
FEF25e75% differed signiﬁcantly among the three groups, and be-
tween each pair of the three groups.
Sputum total cell count differed among the three groups but not
between any pair of groups. As compared with controls, the number
of eosinophils was signiﬁcantly increased in patients with mild
asthma and in those with moderate-to-severe asthma, and the
number ofmacrophageswas signiﬁcantly decreased in patients with
Table 1
Characteristics and outcome of asthmatic patients and healthy controls.
Healthy control
(n ¼ 27)
Asthma p Values
Mild (n ¼ 41) Moderate-to-severe
(n ¼ 19)
2 or 3 Groups Control vs mild Control vs
Moderate-to-severe
Mild vs
Moderate-to-severe
Age (yr) 30 (25e33.8) 48 (32.8e66.8) 57 (38e63.8) <0.0001 <0.0001 <0.0001 NS
Sex (M/F) 17/10 19/22 8/11 NS
Duration of asthma (yr) e 1.5 (0.25e6.5) 2.5 (0.75e7.0) NS
Log IgE (IU/ml) Not tested 2.2 (1.7e2.7) 2.2 (2.1e2.3) NS
Atopy/non-atopy Not tested 30/11 15/4 NS
FEV1 (%pred) 98 (92e107) 91 (83e100) 75 (64e84) <0.0001 0.012 <0.0001 0.0009
FEF25e75% (%pred) 84 (76e96) 61 (45e84) 43 (34e48) <0.0001 0.0004 <0.0001 0.005
Sputum indices
Total cells (105/g) 5.2 (2.1e10.0) 10.8 (5.3e16.8) 13.8 (6.3e26.2) 0.014 NS NS NS
Macrophages (105/g) 5.8 (3.6e16.2) 2.5 (1.3e7.1) 3.6 (1.7e7.7) 0.042 0.013 NS NS
Neutrophils (105/g) 3.6 (2.2e9.8) 2.6 (1.0e12.1) 3.8 (1.7e12.7) NS
Eosinophils (105/g) 0.0 (0.0e0.1) 1.8 (0.4e4.2) 1.2 (0.3e8.7) <0.0001 <0.0001 <0.0001 NS
Epithelial cells (105/g) 0.02 (0.00e0.09) 0.02 (0.00e0.14) 0.08 (0.00e0.40) 0.037 NS 0.013 0.044
PGE2 (ng/g) 1.22 (0.59e1.82) 1.10 (0.28e3.30) 0.65 (0.15e1.34) NS
PGF2a (ng/g) 1.09 (0.54e1.76) 0.79 (0.42e2.21) 1.67 (0.85e3.13) NS
PGD2 (ng/g) 0.23 (0.11e0.56) 0.16 (0.03e0.73) 0.19 (0.07e0.31) NS
TXB2 (ng/g) 1.67 (0.63e3.17) 0.95 (0.22e3.63) 1.92 (1.13e4.00) NS
PGF2aþPGD2þTXB2 (ng/g) 2.89 (1.47e5.21) 2.15 (0.70e6.87) 3.52 (2.15e7.28) NS
PGF2aþPGD2þTXB2/PGE2 2.06 (1.27e5.19) 2.09 (1.05e3.68) 5.15 (2.67e22.17) 0.0006 NS 0.0009 0.0002
FEF25e75%, Mid-forced expiratory ﬂow; PG, prostaglandin; TX, thromboxane; NS, not signiﬁcant.
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in patients with moderate-to-severe asthma than in those withmild
asthma and in controls and but was similar in the latter two groups.
There was no signiﬁcant difference in sputum levels of PGD2,
PGE2, PGF2a, or TXB2 among the three groups (Table 1).
Relationship of sputum prostanoid levels with pulmonary function
in asthmatic patients
The relations between sputum levels of prostanoids and pul-
monary function in the 60 asthmatic subjects are presented in
Table 2. Sputum levels of PGF2a and TXB2 negatively correlatedwith
FEV1 and FEF25e75%. Sputum levels of PGD2 negatively correlated
with FEF25e75%. Sputum levels of PGE2 were not related to any index
of airﬂow obstruction.
Sputum epithelial cell number did not correlate with the
sputum levels of PGD2 (r ¼ 0.03), PGE2 (r ¼ 0.07), PGF2a
(r ¼ 0.13), or TXB2 (r ¼ 0.08) (p > 0.1 for all).
The sputum eosinophil number did not correlate with the
sputum levels of PGD2 (r ¼ 0.03), PGE2 (r ¼ 0.07), PGF2a
(r ¼ 0.13), or TXB2 (r ¼ 0.08) (p > 0.1 for all). The number of mac-
rophages, neutrophils, or epithelial cells was unrelated to any of the
prostanoid levels (data not shown). In the healthy controls, the
sputum levels of prostanoids did not correlate with pulmonary
function or sputum cell differentials (data not shown).
Balance between PGE2 and other prostanoids
The levels of combined PGD2, PGF2a, and TXB2, and their ratio to
PGE2 levels, were calculated in each group to examine the net effectTable 2
Relationship between sputum levels of prostanoids and pulmonary function in 60
asthmatic patients.
FEV1 (%predicted) FEF25e75% (%predicted)
r p r p
PGE2 (ng/g) 0.15 0.26 0.21 0.14
PGF2a (ng/g) 0.33 0.02 0.40 0.004
PGD2 (ng/g) 0.23 0.096 0.36 0.009
TXB2 (ng/g) 0.27 0.05 0.37 0.008
FEF25e75%, mid-forced expiratory ﬂow; PG, prostaglandin; TX, thromboxane.of these “contractile” and “inhibitory” prostanoids. The absolute
levels of PGD2, PGF2a, and TXB2 combined did not differ among
controls and two asthmatic groups (p ¼ 0.13 by ANOVA). However,
the ratio of these levels to PGE2 levels differed among the three
groups, and was highly signiﬁcantly elevated in moderate-to-
severe asthmatics as compared with controls or mild asthmatics,
but was similar in the latter two groups (Table 1, Fig. 1). When the
two asthmatic groups were combined, this ratio signiﬁcantly
correlated with sputum number of epithelial cells (r ¼ 0.39,Fig. 1. The ratio of combined “contractile” prostanoids (prostaglandin D2, prosta-
glandin F2a and thromboxane B2) to prostaglandin E2 in control subjects, mild asth-
matics and moderate-to-severe asthmatics. The ratio differed signiﬁcantly among the
three groups (p ¼ 0.0006), and was greater in moderate-to-severe asthmatics than in
controls (p ¼ 0.0009) and in mild asthmatics (p ¼ 0.0002), but did not differ between
the latter two groups.
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no correlation between the ratio and sputum cell differentials in
control subjects (data not shown).
The combined PGD2/PGF2a/TXB2 levels and PGE2 levels posi-
tively correlated in the controls and in the mild asthmatic group,
but were unrelated in the moderate-to-severe asthmatic group
(Fig. 3).Discussion
There was no signiﬁcant difference in sputum levels of PGD2,
PGE2, PGF2a, or TXB2 among controls, mild asthmatics and
moderate-to-severe asthmatics. Sputum levels of PGD2, PGF2a, and
TXB2, but not those of PGE2, were related to the degree of airﬂow
obstruction in 60 asthmatics. The levels of combined “contractile”
prostanoids (PGD2, PGF2a, and TXB2) did not differ among controls
and two asthmatic groups. However, the ratio of these levels to
PGE2 levels differed among the three groups and was approxi-
mately 2.5-fold greater in moderate-to-severe asthmatics than in
other two groups. The combined PGD2/PGF2a/TXB2 levels positively
correlated with PGE2 levels in controls and in mild asthmatics but
not in moderate-to-severe asthmatics. The sputum epithelial cell
number was signiﬁcantly greater in moderate-to-severe asthmatics
than in other two groups, and positively correlated with PGD2/Fig. 2. The relationship between the ratio of combined “contractile” prostanoids
(prostaglandin D2, prostaglandin F2a and thromboxane B2) to prostaglandin E2 in
moderate-to-severe asthmatics and the number of sputum epithelial cells. Signiﬁcant
positive correlation was found between them.
Fig. 3. The relationship between the levels of combined contractile prostanoids and those o
mild asthmatics but were unrelated in moderate-to-severe asthmatics.PGF2a/TXB2 to PGE2 ratio in 60 asthmatics.We have also shown that
this ratio is increased and correlates with asthma severity, thus
indicating the potential increase in constrictor compared to dilator
prostanoids in asthma. These results suggest that an imbalance in
the production, breakdown, or both between prostaglandin E2 and
other prostanoids may be involved in the pathogenesis of
moderate-to-severe asthma, and that epithelial damage might be
an underlying mechanism for this imbalance.
Potential pathophysiologic roles of prostanoids in asthma have
been extensively studied.1e7,10,11,28e32 PGD2, PGF2a, and TXA2
induce smooth muscle cell contraction and hyperplasia, as well as
mucous hypersecretion in human airway preparations.2,3 In
contrast, PGE2 inhibits various inﬂammatory events, includingmast
cell degranulation, leukotriene B4 production by macrophages, and
eosinophil activation.1,29 Mice deﬁcient in prostanoid receptors
have also been used for in vivo studies. After ovalbumin sensitiza-
tion and challenge, PGD2 receptor-deﬁcient mice failed to develop
Th2 cytokines production, eosinophil inﬁltration, and airway
hyperresponsiveness.30 In sharp contrast, mice lacking PGE2 (EP3)
developed much more pronounced inﬂammation after ovalbumin
than wild-type mice or mice deﬁcient in other PGE2 receptor sub-
types. An EP3-selective agonist suppressed the inﬂammation in
wild-type mice.31 Other study demonstrated that EP4 receptor
knock-out mice had an enhanced cellular inﬂammation.33
Furthermore, cell-based assays using human monocytes or eosin-
ophils showed an inhibition of cytokine release or cyclic AMP
production via activation of the EP4 receptor, suggesting an
endogenous anti-inﬂammatory role for PGE2 acting on the EP4
receptor.33,34 In asthmatic subjects, synthase inhibitors or receptor
antagonists of TX attenuate airway eosinophilia and
hyperresponsiveness.32
Airway levels of endogenous prostanoids have been examined
in asthmatic patients.15e21,34 Bronchoalveolar levels of PGD2,
9a,11b-PGF2, and PGF2a, but not of TXB2, 6-keto-PGF1a or PGE2 were
higher in 15 asymptomatic patients than in 12 normal controls, but
were unrelated to either airway obstruction or hyper-
responsiveness.15 Sputum levels of PGD2, PGE2, PGF2a, and TXB2
were similar in 17 asthmatic patients (8 receiving inhaled cortico-
steroids) and 10 normal controls,17 and failed to correlate with
disease severity or FEV1 values in 10 aspirin-tolerant patients or 13
aspirin-intolerant patients.33 Exhaled breath condensate levels of
PGD2, PGE2, PGF2a, and TXB2 levels were similar between 15 ste-
roid-naïve asthmatics and 12 healthy controls.18 Kostikas et al.19
have examined PGE2 levels in breath condensate of smoking and
nonsmoking mild asthmatics (n¼ 15 for each) and healthy controls
(n ¼ 10 for each). PGE2 levels were higher in asthmatic smokers
than in the other two groups, but no difference was found among
the latter. The increased PGE2 levels in the asthmatic smokers weref prostaglandin E2 in the three groups. They signiﬁcantly correlated in controls and in
M. Takemura et al. / Allergology International 66 (2017) 83e88 87attributed to the activation of airway macrophages by cigarette
smoke.
We have demonstrated, for the ﬁrst time to our knowledge,
contrasting characteristics of endogenous prostanoids in asthmatic
patients, by correlating their sputum levels and pulmonary func-
tion. These are consistent with previous in vitro, animal, and human
studies, that showed a contractile property of PGD2, PGF2a, and
TXB2 but not PGE2, whichmay even be dilatory.2e5,28,30,31 Our study
showed that airway obstruction was greater in moderate-to-severe
asthmatics than in controls and mild asthma, and each sputum
contractile prostanoid level correlated with indices of airway
obstruction. However, the combined contractile prostanoids levels
were not different among the three groups. It is difﬁcult to answer
this discrepancy but it may be due to the inhomogeneous distri-
bution of sputum levels of contractile prostanoids irrespective to
asthma severity and the factors other than prostanoids such as
airway remodeling. Arguably, both “contractile” and “inhibitory”
prostanoids may be active in the asthmatic airways and their net
effects should be considered. Wenzel et al. measured the bron-
choalveolar lavage ﬂuid levels of bronchoconstrictors prostanoids
(PGD2, TXB2) and bronchoprotectors (6-keto-PGF1a, PGE2) before
and after allergen challenge in asthmatic patients. They demon-
strated that the ratio of combined PGD2 and TXB2 to combined PGE2
and 6-keto-PGF1a increased greater than 5-fold in asthmatics after
allergen challenge although the underlying mechanism was not
referred.35 In the present study, the ratio of combined PGD2/PGF2a/
TXB2 levels to PGE2 levels was signiﬁcantly higher in moderate-to-
severe asthmatics than in controls or mild asthmatics, although the
levels of each prostanoid were similar in the three groups. The
levels of combined PGD2/PGF2a/TXB2 positively correlated with
PGE2 levels in the controls and in the mild asthmatic group, but not
in the moderate-to-severe asthmatic group. The effects of “dele-
terious” prostanoids may be counterbalanced by the synthesis of
“inhibitory” prostanoid PGE2 in mild asthmatics, but such mecha-
nism might be deﬁcient in more severe disease.
Previous studies have shown that the number of epithelial cells
in bronchoalveolar lavage or sputum of asthmatic patients is
elevated as compared with healthy controls,12,14 correlates with the
severity of disease14 and airway responsiveness,12 and responds to
intervention in parallel with clinical improvement.13 These indicate
the presence, and pathophysiologic relevance, of epithelial
desquamation or damage in asthma. In our study, the sputum
epithelial cell number was increased in moderate-to-severe asth-
matics as compared with controls and mild asthmatics, and posi-
tively correlated with the PGD2þPGF2aþTXB2/PGE2 ratio in the two
asthmatic subgroups combined. Epithelial damage as suggested in
the latter group might be responsible for this imbalance.
The effect of proinﬂammatory stimuli on PGD2/PGE2 production
by bronchial ﬁbroblasts of aspirin-tolerant and -intolerant asth-
matic patients has been examined.36 Both prostanoids were
increasingly produced, but PGE2/PGD2 concentration ratio elevated
signiﬁcantly less in aspirin-intolerant patients, a severer phenotype
of asthma, than in aspirin-tolerant patients.37 This imbalance in the
prostanoid production by ﬁbroblasts may also explain our results,
but ﬁbroblasts could not be addressed by our sputum study. Other
investigator also demonstrated a dysregulation of PGE2 production
from alveolar macrophage from severe asthmatics.38 We found no
correlation between the sputum PGE2 levels and the number of
sputum macrophages in moderate-to-severe asthmatics, but
cannot exclude the possibility that PGE2 synthesis of alveolar
macrophage is downregulated.
Our asthmatic patients were older than controls. It was very
difﬁcult to obtain an age-matching control group. To our knowl-
edge, there is no evidence that prostanoids production or meta-
bolism could be affected by age. Indeed, our patients and controlsshowed no correlation between age and prostanoid levels (data not
shown). Ex vivo production of eicosanoids is unlikely to have
inﬂuenced our results, because treatment of sputum with agents
blocking ex vivo production and breakdown of prostanoids dose not
affect their concentrations.16
In the decades, evidence has been collected demonstrating the
role of prostanoids in asthma. Recent studies have shown each
prostanoid receptor has multiple functions resulting in opposing
effects, such as deleterious and inhibitory outcomes. Therefore, the
current study supports the view that an imbalance of endogenous
prostanoids may play an important role in the pathophysiology of
asthma. Our ﬁndings provide some insight into the mechanisms of
development of severe asthma and may suggest consideration of a
new therapeutic strategy of asthma.
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